Search

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches

Helping patients by addressing health system gaps

Using AI to power patient-centric guideline optimization

Helping patients by addressing health system gaps

New analytical tool helps optimize patient care

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction

New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec

The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec

Tackling care gaps in respiratory diseases in Alberta

Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases

New partnership in Alberta supports healthcare solutions for interstitial lung diseases

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program

Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

Optimizing oxygen needs for people living with Interstitial Lung Disease

Multidisciplinary care reduces hospitalizations for chronic obstructive pulmonary disease (COPD) patients

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

Helping patients by addressing health system gaps

Using AI to power patient-centric guideline optimization

Helping patients by addressing health system gaps

Helping patients by addressing health system gaps

New analytical tool helps optimize patient care

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec

Tackling care gaps in respiratory diseases in Alberta

Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases

New partnership in Alberta supports healthcare solutions for interstitial lung diseases

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program

Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

Optimizing oxygen needs for people living with Interstitial Lung Disease

Multidisciplinary care reduces hospitalizations for chronic obstructive pulmonary disease (COPD) patients

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 